OpGen (NASDAQ: OPGN) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.
Earnings and Valuation
This table compares OpGen and Codexis’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|OpGen||$4.03 million||2.98||-$19.16 million||($12.67)||-0.19|
|Codexis||$50.02 million||12.37||-$23.00 million||($0.65)||-19.69|
Insider and Institutional Ownership
71.0% of Codexis shares are owned by institutional investors. 17.4% of OpGen shares are owned by insiders. Comparatively, 9.8% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares OpGen and Codexis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for OpGen and Codexis, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OpGen presently has a consensus price target of $9.00, suggesting a potential upside of 268.85%. Codexis has a consensus price target of $11.50, suggesting a potential downside of 10.16%. Given OpGen’s higher possible upside, equities analysts clearly believe OpGen is more favorable than Codexis.
Codexis beats OpGen on 7 of the 11 factors compared between the two stocks.
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.